Focus: C2N Diagnostics is a public-stage company specializing in blood-based diagnostics and therapeutics for Alzheimer's disease and related neurodegenerative conditions. They are positioned as a leader in plasma biomarker testing, particularly tau and phosphorylated tau assays.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow C2N Diagnostics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship diagnostic test actively marketed and used in clinical trials; represents core business model and revenue driver.
Help build intelligence for C2N Diagnostics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from C2N Diagnostics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Next-generation blood test iteration with expanded clinical validation, supporting iterative product enhancement strategy.
Complementary digital diagnostic tool for cognitive assessment, diversifying the portfolio beyond protein biomarkers.
C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s Disease - Business Wire
C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s Disease Business Wire
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership - Indian Pharma Post
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership Indian Pharma Post
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks - Nature
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks Nature
Blood test “clocks” predict when Alzheimer’s symptoms will start - WashU Medicine
Blood test “clocks” predict when Alzheimer’s symptoms will start WashU Medicine
Neurological Biomarkers Market Report 2025-2030, By Offering, Type, and Geo - MarketsandMarkets
Neurological Biomarkers Market Report 2025-2030, By Offering, Type, and Geo MarketsandMarkets
Palm Beach panel discusses breakthroughs in Alzheimer's blood tests - Palm Beach Daily News
Palm Beach panel discusses breakthroughs in Alzheimer's blood tests Palm Beach Daily News
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo